Goldman Sachs Group Inc Atai Life Sciences N.V. Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
A detailed history of Goldman Sachs Group Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 171,592 shares of ATAI stock, worth $341,468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
171,592
Previous 162,765
5.42%
Holding current value
$341,468
Previous $188,000
21.28%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ATAI
# of Institutions
104Shares Held
16.3MCall Options Held
367KPut Options Held
69.2K-
Morgan Stanley New York, NY3.33MShares$6.63 Million0.0% of portfolio
-
Ubs Group Ag1.94MShares$3.86 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$2.6 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny982KShares$1.95 Million0.0% of portfolio
-
Davidson Kempner Capital Management LP New York, NY949KShares$1.89 Million0.03% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $330M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...